Peter Gray - 11 Aug 2023 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Reporting relationship: Director
Issuer ticker: JAZZ
Reported as of: 11 Aug 2023
Net transaction value: -$171,455
SEC form: 4
Accepted by SEC: 15 Aug 2023, 17:47:35 UTC
Prior SEC filing: 22 Aug 2022
Source filing: View source filing
Reporting owner signature: By: /s/Adam Guttmann as attorney in fact For: Peter Gray

Key filing fact

Peter Gray filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 15 Aug 2023.

Key facts

This page summarizes Peter Gray's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 Aug 2023, 17:47.

Change

Previous filing in this sequence was filed on 22 Aug 2022.
Current net transaction value: -$171,455.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JAZZ transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +3,075
Change %: +22%
Price: $0.000000
Shares after: 17,309
Date: 11 Aug 2023
Ownership: Direct
Footnotes: F1

JAZZ transaction

Ordinary Shares

Sale

Transaction value: $171,455
Shares: -1,241
Change %: -7.2%
Price: $138.16
Shares after: 16,068
Date: 14 Aug 2023
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024.

Footnote F2

Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Footnote F3

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.75 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.